Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study to Evaluate the Safety, Tolerability, Pharmacokinetic (PK) Characteristics, and Preliminary Efficacy of MC002 in Participants With Locally Advanced/Metastatic Solid Tumors

NCT07726212 is registered in ClinicalTrials.gov with Hangzhou MacroLink Biopharmaceutical LLC as lead sponsor.

NCT NCT07726212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07726212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study to Evaluate the Safety, Tolerability, Pharmacokinetic (PK) Characteristics, and Preliminary Efficacy of MC002 in Participants With Locally Advanced/Metastatic Solid Tumors
Lead sponsor
Hangzhou MacroLink Biopharmaceutical LLC
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
June 30, 2028
Enrollment
143 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced esophageal cancer, advanced lung cancer